Providing drugs - which might be good due to potentially encouraging companies to access, except for the aforementioned removal of oversight. Critically, neither pathway mandates that companies provide these drugs to anyone (so,RTT is something of a misnomer; it’s more Right to Ask the Pharma Company Access patients typically must pay for them under either paradigm, and many companies prefer EA because they need to work with the FDA anyway to get their drugs approved and there isn’t guidance surrounding. RTT legislation. So it may slightly simplify the process of getting access to the drug by skipping application step, but may leave patients more vulnerabl.
BUY IT:
Nhận xét
Đăng nhận xét